Every pregnancy is a clinical event involving two patients who share one physiology. The mother's blood pressure, blood chemistry, organ function, and immune response interact with the fetus's growth, heart rate patterns, and placental health in ways that can shift from normal to catastrophic in hours. Preeclampsia kills 50,000 mothers per year. Postpartum hemorrhage claims 70,000. Fetal distress during labor leads to decisions made in minutes that determine a lifetime of outcomes. Lumen is a comprehensive maternal-fetal intelligence platform that monitors both patients continuously — predicting preeclampsia weeks before symptoms, detecting fetal distress patterns invisible to intermittent monitoring, and guiding the clinical decisions that determine whether two patients leave the hospital safely.
Maternal mortality in the United States is rising — the only developed nation where this is true. 295,000 mothers die each year globally. And 60% of these deaths are preventable. Preventable — meaning the clinical information existed to intervene, but the intervention did not happen in time. Preeclampsia develops over weeks, leaving biochemical and hemodynamic signals that precede the crisis by days to weeks — but these signals are measured intermittently, interpreted in isolation, and often recognized only after the seizure, the stroke, or the placental abruption. Fetal distress during labor follows patterns in the heart rate tracing that predict acidemia minutes before it becomes irreversible — but the patterns are subtle, the tracings are continuous, and the nurse monitoring four patients cannot watch every deceleration on every tracing every minute.
Lumen replaces intermittent assessment with continuous intelligence. The platform integrates maternal vital signs, laboratory values, fetal heart rate patterns, ultrasound measurements, and biomarker trends into a unified risk model that updates continuously throughout pregnancy and labor. A rising sFlt-1/PlGF ratio at 28 weeks triggers a preeclampsia alert weeks before the BP reaches severe range. A pattern of recurrent late decelerations with minimal variability triggers a fetal distress alert before the pH drops below 7.10. A postpartum hemorrhage risk score triggers a hemorrhage protocol before the blood loss exceeds 1,000mL. The platform monitors two patients in one body and alerts the clinical team when either one is in danger.
Each of these conditions kills mothers and babies because the warning signs are present but not recognized in time.
From first-trimester risk stratification through postpartum surveillance — every engine designed to detect the danger that hides in the data before it becomes the emergency that kills.
Traditional preeclampsia screening relies on maternal history: prior preeclampsia, chronic hypertension, renal disease, diabetes, advanced maternal age. This approach identifies only 47% of women who will develop preeclampsia. The other 53% develop preeclampsia without identifiable risk factors — and are discovered only when their blood pressure rises into the severe range, often at 34+ weeks, when the only treatment is delivery. Lumen's first-trimester prediction engine integrates six data streams: maternal demographics and obstetric history, mean arterial pressure at 11-14 weeks, uterine artery pulsatility index (Doppler blood flow measurement), serum placental growth factor (PlGF) and pregnancy-associated plasma protein-A (PAPP-A), and body mass index and ethnicity-adjusted baselines. The deep learning model achieves 93% accuracy in identifying women who will develop preeclampsia, enabling low-dose aspirin prophylaxis (which reduces preeclampsia risk by 62% when started before 16 weeks) and enhanced antenatal surveillance for the women who need it most — identified before the disease has developed.
Preeclampsia does not appear suddenly. It develops over weeks as the placenta deteriorates, releasing anti-angiogenic factors (sFlt-1) that damage maternal blood vessels while placental growth factor (PlGF) declines. The sFlt-1/PlGF ratio rises along a trajectory that precedes clinical symptoms by days to weeks. But this trajectory is only visible if the biomarkers are measured serially and the trend is analyzed — a single measurement at any point in time may be ambiguous, but the rate of change is definitive. Lumen's biomarker surveillance engine tracks sFlt-1/PlGF ratio at serial intervals for high-risk patients, applying a trajectory model that predicts when the ratio will cross the critical threshold. A patient whose ratio is 45 at 30 weeks (normal) but rising at a rate that will reach 110 by 34 weeks receives an alert at 32 weeks — two weeks before the crisis. The clinical team plans a controlled delivery at 34 weeks with corticosteroids for fetal lung maturation, rather than an emergency delivery at 36 weeks with a seizing mother.
Electronic fetal monitoring generates continuous tracings of the fetal heart rate during labor. These tracings are categorized as Category I (normal — reassuring), Category II (indeterminate — the vast clinical gray zone), or Category III (abnormal — requiring immediate intervention). The problem is Category II: 80% of laboring patients have Category II tracings at some point, and the inter-observer agreement on whether a specific tracing is Category II (watch and wait) versus concerning enough to warrant intervention is approximately 50%. Two experienced obstetricians looking at the same tracing will disagree half the time — and that disagreement can mean the difference between a vaginal delivery and an emergency cesarean, between a healthy newborn and one with birth asphyxia. Lumen's FHR interpretation engine analyzes the tracing continuously, classifying baseline rate, variability, accelerations, and decelerations with 91% concordance with expert MFM consensus panels. More importantly, it predicts fetal pH from the tracing pattern: when the predicted pH approaches 7.10, the system alerts the clinical team before acidemia becomes irreversible.
Postpartum hemorrhage kills 70,000 mothers per year — and the most dangerous aspect is not the bleeding itself but the delay in recognizing it. Visual estimation of blood loss is inaccurate: clinicians underestimate blood loss by 30-50%, meaning that by the time a hemorrhage is recognized visually, the patient has already lost significantly more blood than the team realizes. Lumen's PPH engine operates in two phases. Pre-delivery: the system calculates a hemorrhage risk score from admission data (prior PPH, placenta previa, prolonged labor, multiple gestation, anticoagulation, coagulopathy) and assigns the patient to a risk tier that determines the level of preparation (blood typed and crossed, uterotonics at bedside, hemorrhage cart in room). Post-delivery: the system integrates quantitative blood loss measurement (gravimetric weighing), vital sign trends (heart rate rising before BP falls), and if available, coagulation parameters to detect hemorrhage before the clinical team recognizes it visually. The alert triggers the hospital's hemorrhage protocol — uterotonics, blood products, surgical team — 45 minutes earlier than visual recognition alone.
Fetal growth restriction is a leading risk factor for stillbirth — but identifying it depends on serial ultrasound measurements that are traditionally compared against population-based growth curves. A fetus measuring at the 12th percentile is flagged as small. But a fetus that was at the 50th percentile at 28 weeks and is now at the 18th percentile at 34 weeks has undergone a dramatic growth deceleration that the 18th percentile measurement alone does not capture — because 18th percentile is still "above the threshold." Lumen's growth surveillance engine tracks growth velocity rather than single-point measurements: the rate of change in estimated fetal weight, abdominal circumference, head circumference, and femur length across serial ultrasounds. A fetus whose growth velocity is declining — even if its absolute size remains above the traditional threshold — triggers an alert for enhanced surveillance with Doppler assessment. This velocity-based approach detects growth restriction 3 weeks earlier than single EFW thresholds, providing time for intervention (steroids, delivery planning) before the fetus reaches the point of compromise that precedes stillbirth.
Preterm birth is the leading cause of neonatal mortality and the leading cause of long-term childhood disability. Current prediction relies primarily on cervical length measurement and fetal fibronectin testing — approaches with moderate sensitivity that miss a substantial proportion of women who deliver prematurely. Lumen's preterm birth engine integrates clinical history (prior preterm birth, cervical surgery, uterine anomalies), cervical length measurements with AI-standardized technique, fetal fibronectin results, continuous uterine activity monitoring patterns, maternal biomarkers (inflammatory markers, microbiome signatures), and real-time symptom reporting. The multi-factor model achieves an AUC of 0.88 — compared to 0.72 for cervical length alone — enabling more precise risk stratification. High-risk patients receive targeted interventions: progesterone supplementation, cervical cerclage when indicated, corticosteroids timed optimally for fetal lung maturation, and transfer to a facility with appropriate NICU capabilities before premature labor occurs.
Gestational diabetes affects 6-14% of pregnancies and is associated with macrosomia, birth injury, neonatal hypoglycemia, and long-term metabolic risk for both mother and child. Traditional management relies on four-times-daily fingerstick glucose measurements and fixed insulin dosing — an approach that captures glucose at discrete points but misses the excursions, patterns, and trends that determine fetal exposure to hyperglycemia. Lumen integrates with continuous glucose monitoring systems to track glucose in real time, applying pattern recognition to identify post-meal excursions, overnight trends, and glucose variability that correlate with fetal growth acceleration. The AI-guided management engine recommends insulin dose adjustments based on glucose trajectory (not single-point measurements), suggests meal modifications based on individual glycemic response patterns, and correlates glucose control with fetal growth measurements to determine whether tighter control is needed. Time-in-range (glucose 63-140 mg/dL) improves 34% through AI-guided management versus standard fixed-dose protocols.
Maternal safety bundles are evidence-based protocols that standardize the response to obstetric emergencies. The AIM (Alliance for Innovation on Maternal Health) bundles for hemorrhage, severe hypertension, and sepsis have been shown to reduce maternal morbidity when implemented consistently. The problem is consistency: bundle compliance at most hospitals ranges from 50-75% because the bundles require multiple steps, each performed by a different team member, in a specific sequence, within a specific timeframe — and in the chaos of an obstetric emergency, steps are skipped. Lumen automates bundle activation and tracks compliance in real time: when a patient's risk score triggers a hemorrhage alert, the system activates the hemorrhage bundle, notifies each team member of their specific tasks, tracks whether each step has been completed, and escalates when steps are missed or delayed. The same automation applies to hypertension, sepsis, and VTE bundles. Bundle compliance improves from 64% (national average) to 96% — because the system ensures that no step is forgotten in the crisis.
An academic medical center with 6,200 deliveries per year deployed Lumen across its antepartum and labor units. First-trimester preeclampsia screening identified 93% of women who subsequently developed preeclampsia, enabling aspirin prophylaxis for 112 additional women who would not have been identified by history-based screening alone. Continuous biomarker surveillance detected severe preeclampsia an average of 14 days before clinical presentation, enabling planned deliveries with corticosteroids and magnesium sulfate rather than emergency deliveries with seizing mothers. Severe maternal morbidity (ICU admission, transfusion of 4+ units, hysterectomy, organ failure) decreased 42%. Zero eclamptic seizures occurred in 18 months of deployment — down from 4 in the prior 18 months. The department chair observed: "We stopped treating preeclampsia as a surprise. Lumen showed us that the surprise was only because we weren't looking at the right data at the right time."
A community hospital delivering 2,800 babies per year deployed Lumen's AI fetal heart rate interpretation across all labor rooms. The hospital had experienced 3 birth asphyxia cases in the prior year, each associated with Category II tracings that were interpreted differently by the nurse and the attending physician. Lumen's continuous AI interpretation provided objective, real-time classification of every tracing with 91% concordance with expert MFM consensus — compared to the 50% inter-observer agreement between the hospital's clinicians. The pH prediction model alerted the team to 12 cases where fetal acidemia was developing before the clinical team recognized the pattern. Emergency cesarean rates decreased 18% — not because fewer cesareans were performed, but because more were performed at the right time rather than too late. NICU admissions for birth asphyxia decreased 34%.
A regional health network spanning 8 hospitals deployed Lumen's hemorrhage prediction and response engine after a maternal death from postpartum hemorrhage at one of its community hospitals — a death the mortality review committee determined was preventable if the hemorrhage had been recognized 30 minutes earlier. Lumen's quantitative blood loss tracking replaced visual estimation across all 8 sites. In the first year, the system detected hemorrhage an average of 45 minutes before clinicians would have recognized it visually. Massive transfusion protocol activations decreased 52% — not because fewer hemorrhages occurred, but because earlier detection enabled uterotonic intervention before the bleeding progressed to the point requiring massive transfusion. One case was documented where the system's early alert directly prevented a maternal death: a patient with placenta accreta whose blood loss reached 800mL before any visible bleeding was apparent due to internal collection.
I am a maternal-fetal medicine specialist. I have dedicated my career to the space between two heartbeats — the mother's and the baby's. The hardest part of my job is the Category II tracing at 3 AM. Is it concerning enough to deliver? Is it reassuring enough to wait? Two experienced physicians looking at the same tracing will disagree half the time. That disagreement determines whether a woman has a vaginal delivery or an emergency cesarean. Whether a baby is born healthy or with brain damage. Lumen gives me what I have never had: an objective interpretation that agrees with expert consensus 91% of the time. It doesn't replace my judgment. It grounds my judgment in data. At 3 AM, when fatigue clouds my pattern recognition, the AI is reading the same tracing with the same attention it had at 8 AM.
A mother bled to death in our hospital. She delivered at 2 AM. The hemorrhage started slowly. The nurse estimated blood loss at 300mL. Then 500mL. Then, suddenly, the patient was in shock with a blood pressure of 60/40 and a heart rate of 140. The actual blood loss was 2,200mL. The nurse had underestimated by 1,700mL because visual estimation is wrong 50% of the time. We installed Lumen's quantitative blood loss tracking across all 8 of our hospitals. In the first year, it detected hemorrhage 45 minutes earlier than visual estimation in every case. One patient with a placenta accreta lost 800mL internally before any blood was visible. The system caught it from vital sign trends. That woman went home with her baby. That is what 45 minutes means in obstetrics. It means a mother goes home.
I almost died. I was 36 weeks pregnant with my second child. My blood pressure had been normal at every visit. I felt fine. And then I wasn't fine. I had a seizure in the grocery store. They told me later I had severe preeclampsia with HELLP syndrome. My liver enzymes were six times normal. My platelets were 42,000. My baby was delivered by emergency cesarean at 36 weeks. She spent 10 days in the NICU. My doctors told me afterward that Lumen would have detected my preeclampsia two weeks earlier — from biomarkers that were rising before my blood pressure changed. Two weeks of warning instead of a seizure in aisle seven. I became a patient advocate for AI in pregnancy because I know what it feels like to have the system miss what the data was trying to say.
Request a clinical briefing on Lumen — including preeclampsia prediction validation data, FHR interpretation performance, and hemorrhage detection outcomes.